Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CRS 207

Drug Profile

CRS 207

Alternative Names: ANZ-207; Cancer vaccine - Aduro BioTech; CRS-207; Listeria monocytogenes-expressing mesothelin - Aduro Biotech

Latest Information Update: 15 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cerus Corporation; Chugai Pharmaceutical; Johns Hopkins University
  • Developer Aduro BioTech; Merck AG
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants; Megakaryocyte potentiating factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Mesothelioma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Fallopian tube cancer; Gastric cancer; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 23 Jan 2018 Sidney Kimmel Comprehensive Cancer Center initiates enrolment in a phase II trial for Pancreatic cancer (Metastatic disease, Combination therapy, Second-line therapy or greater) in USA (NCT03006302)
  • 18 Dec 2017 Discontinued - Phase-I/II for Peritoneal cancer (Combination therapy, Second-line therapy or greater) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top